Terumo enters purchase agreement for XPro large bore vascular closure system


Terumo has entered into a definitive asset purchase agreement with Medeon Biodesign for its XPro large bore vascular closure system. The transaction consists of an up-front payment of US$20 million and milestone payments.

According to a press release, Medeon will continue to provide its strong expertise in product innovation in collaboration with Terumo for future technical, clinical and regulatory developments of the closure system.

The XPro large bore vascular closure system is an automated suture-mediated closure device to simultaneously deliver two pairs of sutures, specifically targeting percutaneous large bore procedures, including transcatheter aortic valve implantation (TAVI), endovascular aneurysm repair (EVAR), thoracic endovascular aneurysm repair (TEVAR), and percutaneous balloon aortic valvuloplasty procedures.

The product’s safety and effectiveness have been successfully demonstrated through a CE marking clinical study in New Zealand, Australia, and Taiwan, with patients undergoing percutaneous endovascular procedures utilizing 8–18F introducer sheaths via the common femoral artery. The device achieved immediate or rapid haemostasis at the puncture sites with excellent clinical outcomes, including fast ambulation and discharge from hospitals.

“Access site complications in large bore procedures remain a significant concern among practicing clinicians. Leveraging the advantages of the security of suture-mediated closure and built-in safety mechanisms, the closure system provides a better solution for the large bore procedures with excellent outcomes and rapid haemostasis. We are pleased that the closure system’s unique and innovative technology complements Terumo’s vascular closure device portfolio, and we look forward, together with Terumo’s strong expertise in product development and commercialisation, to accelerating the time to market of the closure system in the emerging large bore market and driving further innovation into the hands of healthcare providers,” says Yue-Teh Jang, chairman and CEO of Medeon.



Please enter your comment!
Please enter your name here